Abstracts tagged "Anti-TNF Drugs"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Anna Sutton¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…
Abstract Number: 1657 • ACR Convergence 2025
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Brenda Miao¹, Marie Binvignat², Augusto Garcia-Agundez³, Maxim Bravo⁴, Christopher Williams⁵, Claire Miao⁴, Ahmed Alaa⁶, Vivek Rudrapatna⁵, gabriela Schmajuk⁷ and Jinoos Yazdany³, ¹UCSF, Fremont, CA, ²Sorbonne University, Paris, France, ³UCSF, San Francisco, CA, ⁴UC Berkeley, San Francisco, ⁵UCSF, San Francisco, ⁶UC Berkeley, Berkeley, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are cornerstones of autoimmune‑disease therapy, yet many patients switch agents because of loss of effectiveness, adverse events, or insurance…
Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Rachael Stovall¹, Cinthia Blat², Eric Roberts³, Jean Liew⁴, Katherine Wysham⁵, Namrata Singh¹, Janna Friedly¹, Lianne S. Gensler⁶, gabriela Schmajuk⁷ and Jinoos Yazdany⁸, ¹University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, SF, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁸UCSF, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…
Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Dawn Gist¹, Andrea Ramirez¹, Jamie Lai², Duc Nguyen¹ and Kexin Guo¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, The Woodlands, TX
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Alexia Zagouras¹, Sammy Pickell¹, Yuhan Liu¹, Ronald Witteles¹ and Matthew Charles Baker², ¹Stanford University, Stanford, CA, ²Stanford University, Menlo Park, CA
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Kathryne Marks¹, Alice Horisberger², Ifeoluwakiisi Adejoorin¹, Leah Santacroce¹, Mehreen Elahee³, Joan Bathon⁴, Kevin Wei⁵, Daniel Solomon⁶ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³Brigham and Women's Hospital, Wexford, PA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Task Toyoda¹, Kerem Abacar¹, Farag Shuweihdi², Megan Sheridan³, Jacqueline Nam³, Ai Lyn Tan⁴, Lesley-Anne Bissell³, Paul Emery⁵ and Kulveer Mankia⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ²Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ⁵University of Leeds, Leeds, England, United Kingdom
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 0537 • ACR Convergence 2025
HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
Kent LE¹, Hervé LOCRELLE¹, Myriam NORMAND¹, Irina COMAN¹, Louis DELENTE¹, Tiphany NEEL¹, Adamah AMOUZOUGAN¹, Thierry THOMAS¹ and Hubert Marotte², ¹Service Rhumatologie Hôpital Nord, Saint-Etienne, France, ²INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France
Background/Purpose: To assess the prevalence, risk factors and treatment-related outcomes of uveitis in patients with spondyloarthritis (SpA), using data from a 15-year real-life cohort.Methods: We…

1
2
3
…
21
Next Page »